Cardiorenal syndrome is a spectrum of disorders affecting the heart and kidneys. Dysfunction in either organ can trigger negative changes in the other. Properly functioning heart and kidneys are ...

A panel of experts led by Neil Minkoff, MD, discuss health care resource utilization and economic burden associated with cardiorenal metabolic syndrome. Neil Minkoff, MD: Having been a primary care ...

Jeffrey Turner, MD, discusses the discovery of cardiovascular and renal benefits in SGLT2 inhibitors, and Nihar R. Desai, MD, MPH, provides insight into the role of SGLT2 inhibitors in the four ...

Interactions between the heart and kidney form the basis of cardiorenal syndrome, which is a heterogeneous and complex clinical entity associated with substantial morbidity and mortality Precise ...

Please provide your email address to receive an email when new articles are posted on . The Cover Story this month in Healio/ Nephrology News & Issues focuses on obesity and its relationship to ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Chiadi E. Ndumele, ...

AstraZeneca will acquire CinCor Pharma in a deal that aims to boost the British pharma giant’s cardiorenal pipeline, the company announced Monday. The $1.8 billion deal will give AstraZeneca CinCor’s ...

MannKind Corporation (NASDAQ:MNKD) on Monday agreed to acquire scPharmaceuticals Inc. (NASDAQ:SCPH) for a deal value of up to approximately $360 million, or $5.35 per share. The deal marks MannKind’s ...

Cardiorenal syndrome (CRS) is a spectrum of disorders affecting both the heart and kidneys in which acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other. 1,2 ...